Dr. Shiven B. Patel, FACP, MBA, MD

Dr. Patel practices at University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah.

Dr. Patel's NPI, 1023276490, was assigned on June 1, 2008. Dr. Patel holds Utah license 8291234-1205.

Dr. Patel's primary practice is University of Utah Hospitals and Clinics - Unit, at 50 North Medical Drive, Salt Lake City, UT 84132 in Salt Lake County. The practice phone is (801) 581-2337.

Dr. Patel's primary practice is University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah. Dr. Patel is also affiliated with University of Utah Hospital. The medical group on file is University of Utah Health. Dmand AI also links Dr. Patel to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Patel practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Patel's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Patel is board certified in hematology by the American Board of Internal Medicine. Dr. Patel is licensed in Utah.

CMS data shows 303 Medicare services from Dr. Patel across 4 procedure codes in 2024, for 63 Medicare patients. Medicare paid $17,485 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 63 Medicare patients who saw Dr. Patel in 2024. The largest group is 65 to 74, with 32 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 2.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Patel's median patient age at 73, with 46% women.

In 2024, Dr. Patel wrote 184 Medicare Part D claims for 34 patients. 80% of them were for generic drugs. CMS names the drug for 67 of them, across 4 drugs with 11 or more claims each, at $14,773 in total drug cost. In 2023, CMS named 28 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Patel for performance year 2024, reported as part of a group. Dr. Patel accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Patel as offering telehealth.

Dmand AI links 32 papers to Dr. Patel, published from 2011 to 2024. 2017 was the busiest year, with 4. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Neoplasm Metastasis and Antineoplastic Agents. Dr. Patel has published most often in J Oncol Pharm Pract. Dr. Patel's most frequent co-authors are Sonam Puri, MBBS, David Michael Gill and Srinivas Kiran Tantravahi, MD.

Dmand AI links Dr. Patel to 6 clinical trials, 2 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Lung Neoplasms and Carcinoma, Bronchogenic. National Cancer Institute (NCI) sponsors the most, 4.

CMS Open Payments shows 250 general payments to Dr. Patel from 28 drug and device companies from 2017 to 2025. Speaker and faculty fees make up the largest share, 64% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $70,876.